Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice.
The quinoline-3-carboxamide, Linomide, has been shown to possess potent immunomodulatory activity. We have evaluated the effect of Linomide in the type II collagen induced arthritis in mice. Treatment with Linomide (1.25-80 mg/kg/day) from the day of immunization strongly suppressed the arthritic response. On the other hand, initiation of treatment (20-80 mg/kg/day) at the onset of arthritis resulted in an increased severity of the arthritis. These potent and contradictory effects of Linomide, depending on treatment regime, indicates that central immuno-regulatory functions are affected and that this compound may be a useful tool for the understanding of autoimmune mechanisms.
Björk
J
J
Department of Inflammation Research, Pharmacia LEO Therapeutics, Uppsala, Sweden.
Kleinau
S
S
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000906:Antibodies / Q000032:analysis; D001168:Arthritis / Q000188:drug therapy*; D001169:Arthritis, Experimental / Q000188:drug therapy*; D003094:Collagen; D006912:Hydroxyquinolines / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000906:Antibodies; D006912:Hydroxyquinolines; C045282:roquinimex; D003094:Collagen